Northwest Biotherapeutics Long-Term Phase I and Phase I/II Trial Data Continue to Show Striking Improvement in Survival of Brain Cancer Patients Who Receive DCVax(R)-Brain

BETHESDA, Md., Sept. 11 /PRNewswire-FirstCall/ -- Northwest Biotherapeutics, Inc. ("NWBT" or the "Company") today announced the most recent long-term follow-up data, through June 15, 2008, from its prior Phase I and Phase I/II clinical trials with DCVax(R)-Brain, which began in 2000 and 2003, for patients with Glioblastoma multiforme, the most lethal type of brain cancer. This long-term data...